Methods For The Prediction Of Acute Respiratory Distress Syndrome

Abstract

The invention relates to a method for predicting the risk of developing acute respiratory distress syndrome (ARDS). Prediction of ARDS remains challenging despite available clinical scores. The inventors aimed to assess soluble isoforms and gene variants of the receptor for advanced glycation end-products (RAGE), as predictors of ARDS in a high-risk population. The inventors conducted a multicenter, prospective study including 500 adult patients with at least one ARDS risk factor upon admission to intensive care units. Plasma soluble RAGE (sRAGE) and endogenous secretory RAGE (esRAGE) were measured at baseline and 24 hours later, and four RAGE single nucleotide polymorphisms (SNPs). The primary outcome was ARDS development within seven days. Higher baseline and day one plasma sRAGE and the RAGE rs2070600 SNP were independently associated with an increased rate of ARDS development. Thus, the invention relates to a method for predicting the risk of having or developing ARDS in a patient in need thereof, comprising the step of determining the expression level of Plasma sRAGE and/or detecting RAGE SNP rs2070600 in a biological sample obtained from said patient.


Claims
Download PDF
Document Preview
Document History
  • Publication: Nov 8, 2018
  • Application: May 3, 2018
    WO EP 2018061382 W
  • Priority: May 4, 2017
    EP EP 17305505 A

Download Citation


Sign in to the Lens

Feedback